Shares in Cytori Therapeutics (NSDQ:CYTX) fell today after the biotech missed sales expectations on Wall Street with its second quarter results, but topped EPS estimates. The San Diego, Calif.-based company posted a net loss of -$6 million on sales of $1.5 million for the 3 months ended June 30, for bottom-line growth of 6% on sales loss […]
Cytori Therapeutics
Cytori launches next-gen Celution cell therapy tech
Cytori Therapeutics (NSDQ:CYTX) said today that the next-gen version of its Celution cell therapy device is available for pre-order and that the 1st shipments will start in the 3rd quarter of 2017. The San Diego-based company’s Celution system automates the extraction and concentration of autologous, clinical-grade adipose-derived regenerative cells. The next-gen Celution tech includes new […]
Cytori prices $9.5m public offering
Cytori Therapeutics (NSDQ:CYTX) said today that it priced an underwritten public offering of 8.6 million shares of common stock at $1.10 apiece. The company plans to bring in $9.5 million. Cytori granted a 45-day underwriter’s option to purchase up to 15% of additional shares of common stock. The offering is expected to close on April […]
Cytori wins FDA nod for cell therapy pilot trial
Cytori Therapeutics (NSDQ:CYTX) said today that the FDA approved an Investigational Device Exemption for a pilot trial of the company’s cell therapy in patients with thermal burn injury. The Relief trial is a part of Cytori’s ongoing R&D efforts under its contract with the U.S. Dept. of Health & Human Services’ Biomedical Advanced Research and […]
Cytori launches nanoparticle program after acquiring Azaya Therapeutics
Cytori Therapeutics (NSDQ:CYTX) said yesterday that it completed its acquisition of San Antonio-based Azaya Therapeutics and its nanoparticle cancer drugs. In late January, San Diego-based Cytori said it planned to buy Azaya in a stock deal, offering Azaya shareholders $2 million in CTYX stock. Cytori also said that it paid $2 million upfront for costs associated […]
Cytori buys Azaya’s nanoparticle tech in stock deal
Cytori Therapeutics (NSDQ:CYTX) said this week that it bought San Antonio-based Azaya Therapeutics and its nanoparticle cancer drugs in a stock deal. Azaya shareholders will receive $2 million in CTYX stock. San Diego-based Cytori will also pay $2 million upfront for costs associated with Azaya’s new manufacturing facility in San Antonio. Cytori will acquire a […]
Cytori touts regenerative cell therapy data
Cytori Therapeutics (NSDQ:CYTX) touted the publication of preclinical safety and efficacy data for its cell therapy treatment for combined radiation and thermal injury. The San Diego-based company said the current healthcare system is ill-prepared to care for large numbers of patients that require simultaneous treatment and that patients with severe burns commonly suffer with prolonged […]
Cytori Therapeutics closes $17m funding round
Cytori Therapeutics (NASDAQ:CYTX) said today it closed a $17.1 million rights offering round, floating 6.7 million units at $2.55 each. Through the rights offering, each of the 6.7 million units consisted of an equal amount of shares of common stock and 3.4 million warrants exercisable for 1 share of common stock at $3.06 per share, the company […]
Philips Healthcare’s India chief takes over new emerging markets biz | Personnel Moves
Royal Philips (NYSE:PHG) has promoted its India managing director and CEO Krishna Kumar to a position managing its emerging healthcare business division, according to The Times of India. Kumar is slated to continue as managing director of Philips India division until December, at which point he will lead the development of consumer and profesisonal healthcare […]
FDA OKs Phase II trial for Kerastem’s alopecia treatment
Kerastem Technologies said today it won Investigative Device Exemption approval from the FDA to conduct a clinical trial of its Celution technology used to treat female and early male androgenic alopecia. The 70-patient phase II Style trial will follow-up on initial clinical work in Europe and Japan that the company used for IDE submission, the company […]
